NUTX Nutex Health Inc.
Services-Business Services, NEC · Nasdaq · SEC CIK 1479681 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.8%
TTM net income YoY36.5%
TTM EPS YoY20.0%
Revenue 3-yr CAGR50.9%
Net income 3-yr CAGR—
Margins
Gross margin47.8%
Operating margin39.0%
Net margin20.7%
FCF margin31.1%
EBITDA margin41.8%
Returns
ROE43.8%
ROA16.5%
ROIC (approx.)117.4%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets47.6%
Debt / equity0.10x
Current ratio4.76x
Interest coverage16.21x
Cash quality & payout
Operating cash flow / net income1.57x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $875.26M | $479.95M |
| Gross profit | $444.28M | $196.26M |
| SG&A expense | $51.65M | $41.92M |
| Operating income | $275.62M | $130.70M |
| Interest expense | $22.23M | $19.93M |
| Pretax income | $244.78M | $109.83M |
| Income tax | $64.42M | $15.02M |
| Net income | $70.79M | $52.10M |
| EBITDA | $296.15M | $149.67M |
| EPS (basic) | 11.13 | 10.23 |
| EPS (diluted) | 10.48 | 9.69 |
| Weighted avg. shares (diluted) | 6.76M | 5.49M |
| Balance sheet | ||
| Cash & equivalents | $185.57M | $40.64M |
| Receivables | — | $232.45M |
| Inventory | $2.87M | $2.85M |
| Current assets | $538.81M | $292.48M |
| PP&E, net | $94.58M | $77.93M |
| Goodwill | $13.92M | $13.92M |
| Intangibles | $21.23M | $15.53M |
| Total assets | $918.52M | $655.32M |
| Current liabilities | $157.91M | $154.22M |
| Short-term debt | $13.34M | $14.39M |
| Long-term debt | $29.17M | $22.47M |
| Total debt | $42.51M | $36.86M |
| Total liabilities | $495.09M | $466.79M |
| Shareholders' equity | $329.45M | $132.44M |
| Net debt | -$143.06M | -$3.78M |
| Shares outstanding | 7.09M | 5.51M |
| Cash flow statement | ||
| Operating cash flow | $248.12M | $23.15M |
| Capital expenditure | $2.53M | $2.30M |
| Free cash flow | $245.60M | $20.85M |
| Investing cash flow | -$5.24M | -$5.61M |
| Financing cash flow | -$97.95M | $1.09M |
| Depreciation & amortization | $20.53M | $18.97M |
| Stock-based compensation | $107.78M | -$129,743 |
| Share buybacks | $5.00M | $0 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.